Van Giau Vo, An Seong Soo A
Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam, South Korea.
Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam, South Korea.
J Neurol Sci. 2016 Jan 15;360:141-52. doi: 10.1016/j.jns.2015.12.005. Epub 2015 Dec 4.
Alzheimer's disease (AD) is the most common progressive degenerative disorder, and is characterized by memory loss and cognitive decline. It is a complex disorder with both environmental and genetic components. Current diagnosis of AD is based primarily on the analysis of the patient's cognitive function using imaging techniques and the biochemical analyses of bodily fluids. Efforts have been made to develop not only an effective therapeutic, but also a diagnostic capable of identifying AD before the onset of irreversible neurological damage. The molecular content of exosomes is a fingerprint of the releasing cell type and its status. A significant body of literature has demonstrated that molecular constituents of exosomes, especially exosomal proteins and microRNAs (miRNAs), hold great promise as novel biomarkers for clinical diagnosis. In addition, expression profiling of miRNAs found in nanovesicles has revealed diagnostic potential in neurodegenerative diseases. Currently, exosomal miRNAs within biological fluids are known as good disease-related markers, and have emerged as a powerful tool for solving many difficulties in both the diagnosis and treatment of AD patients. In this review, we reviewed recent advances in the research of exosomal biomarkers as well as exosomal miRNAs, summarized of actively used approaches to identifying potential miRNA biomarkers through mouse models and their potential application in clinical diagnostics in AD. We also supply a comprehensive overview of the formation, function, and isolation of exosomes.
阿尔茨海默病(AD)是最常见的进行性退行性疾病,其特征为记忆力丧失和认知功能衰退。它是一种具有环境和遗传因素的复杂疾病。目前AD的诊断主要基于使用成像技术对患者认知功能的分析以及对体液的生化分析。人们不仅致力于开发有效的治疗方法,还致力于开发一种能够在不可逆神经损伤发生之前识别AD的诊断方法。外泌体的分子内容是释放细胞类型及其状态的指纹。大量文献表明,外泌体的分子成分,尤其是外泌体蛋白和微小RNA(miRNA),作为临床诊断的新型生物标志物具有巨大潜力。此外,在纳米囊泡中发现的miRNA表达谱分析揭示了其在神经退行性疾病中的诊断潜力。目前,生物体液中的外泌体miRNA被认为是良好的疾病相关标志物,并已成为解决AD患者诊断和治疗中诸多难题的有力工具。在本综述中,我们回顾了外泌体生物标志物以及外泌体miRNA研究的最新进展,总结了通过小鼠模型识别潜在miRNA生物标志物的常用方法及其在AD临床诊断中的潜在应用。我们还对外泌体的形成、功能和分离进行了全面概述。